Comparison of three‐year clinical outcomes between sirolimus‐versus paclitaxel‐eluting stents in diabetic patients: Prospective randomized multicenter trial |
| |
Authors: | Soon Jun Hong MD Moo Hyun Kim MD Kwang Soo Cha MD Hun Sik Park MD Shung Chull Chae MD Seung Ho Hur MD Hyeon Cheol Gwon MD Jang Ho Bae MD Do‐Sun Lim MD PhD FACC |
| |
Institution: | 1. Department of Cardiology, Korea University Anam Hospital, Seoul, Korea;2. Department of Cardiology, Donga University Hospital, Pusan, Korea;3. Department of Cardiology, Kyungpook National University Hospital, Daegu, Korea;4. Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea;5. Department of Cardiology, Samsung Medical Center, Seoul, Korea;6. Department of Cardiology, Konyang University Hospital, Daejeon, Korea |
| |
Abstract: | Background : Three‐year follow‐up of major adverse cardiovascular event (MACE) (death, nonfatal myocardial infarction, target lesion revascularization) and the predictors of MACEs in diabetic patients after sirolimus‐eluting stent (SES) or paclitaxel‐eluting stent (PES) implantation have not been reported. Methods : Diabetic patients with de novo coronary lesions (169 patients with 190 lesions) were randomly assigned prospectively to either SES or PES. Results : Baseline characteristics were similar between the two groups. The rates of MACEs 5.9% (n = 5) in the SES vs. 9.5% (n = 8) in the PES Group, P = 0.374] and definite stent thrombosis 1.2% (n = 1) in the SES vs. 3.6% (n = 3) in the PES Group, P = 0.368] were similar in the two groups during the three‐year follow‐up. Multivariate logistic analysis showed that insulin treatment was the only independent predictor of MACE odds ratio (OR) 8.60, 95% confidence interval (CI) 3.25–22.76, P < 0.001] and target vessel revascularization (TVR) (OR 9.50, 95% CI 3.07–29.44, P < 0.001) during the three‐year follow‐up. Conclusions : The rates of MACEs, TVR, and stent thrombosis during the three‐year follow‐up were similar in the SES and PES Groups. Insulin treatment was a main predictor of MACEs and TVR during the three‐year follow‐up after either SES or PES implantation. © 2009 Wiley‐Liss, Inc. |
| |
Keywords: | drug‐eluting stents diabetes mellitus survival analysis major adverse cardiac event stent thrombosis |
|
|